Modeling & Simulation Workshop – China​

Caroline is a Portfolio Account Manager at Certara specializing in modeling and simulation, including QSP, PBPK, and Pharmacometrics. She joined Certara via the acquisition of Applied BioMath, which focused on QSP for complex biologics. With a background in biochemistry and medicine, she is passionate about accelerating better therapeutics to patients through modeling and simulation.

Jia Ning, PhD joined Certara’s Simcyp group in 2019. She is primarily responsible for establishing PBPK models for drugs, predicting drug-drug interactions (DDI), and predicting pharmacokinetics (PK) in special populations.

She conducted research at Wageningen University in the Netherlands from 2015 to 2019. She excels in using PBPK models to predict hepatotoxicity of drugs and comparing differences between species and ethnic groups.

Dr Yu-Wei Lin is Senior Director of Pharmacometrics and APAC Quantitative Sciences Solutions Team Lead at Certara. He is an experienced pharmacometrician with expertise across population PK/PD, exposure–response, translational modelling, and model-informed drug development. His work spans oncology, monoclonal antibodies, antibody–drug conjugates, infectious diseases, and complex biologics, supporting dose optimization, regulatory strategy, and clinical development decision-making.​

​Dr Lin has led and contributed to global modelling and simulation programs across early- and late-stage development, including ADC-related quantitative pharmacology strategies. In addition to his role at Certara, he holds academic appointments and maintains an active research portfolio in antimicrobial PK/PD, AI-enabled pharmacometrics, and translational drug development.​

Alex has over 30 years’ experience in the pharma industry, having worked in both biotechs and large pharma including Novartis, UCB and GSK. For the last 15 years he has been working in market access consultancy helping global clients achieve their access and commercial goals.

Ruijuan Zhu graduated from East China Normal University and worked as a visiting scholar at the University of Houston, US. As a specialist in bioinformatics, she has accumulated extensive experience in disease detection and pharmaceutical R&D. Now serving as a solutions consultant at Certara, she masters the application of D360 for expediting drug discovery, proficiently analyzes and reviews nonclinical data via SEND Explorer, and fully understands how P21E enables CDISC-aligned data organization and streamlines project regulatory submissions.​